ince the earliest descriptions of pain related to injury of the nervous system, it has been recognized that the characteristics of this type of pain differ markedly from those of pain due to nonneural tissue damage. Later as new analgesics were developed, it became clear that neurogenic pain was very often refractory to these drugs. Recently neuropathic pain is defined as "pain initiated or caused by a primary lesion or dysfunction in the nervous system." Inflammatory reaction and neuropathic pain are often considered to be distinct entities. The development of neuropathic pain involves not only neuron but also inflammatory cells, chemokines, and glial cells. Treatment of neuropathic pain is difficult and frequently unrewarding. The basic principles are the identification and elimination of the underlying pathologic mechanism that maintains central sensitization; the use of nonsteroidal anti-inflammatory drugs to reduce peripheral sensitization and modulate the activity of nociceptors; the use of tricyclic antidepressants to induce sleep and decrease lancinating and burning neuropathic pain; a trial of gabapentin, pregabalin, lamotrigine and topamax; the use of lidocaine patch for intractable trigeminal neuralgia; sympathetic blockade for complex regional pain syndrome while patients are stick sympathetically maintained; dorsal column stimulation; intrathecal therapies including morphine, clonidine, and GABA B agonists when other less invasive therapies have failed. In this article we reviewed the role of peripheral inflammation for development of neuropathic pain, diagnosis, and new opportunities for treatment of neuropathic pain, especially focused on medical treatments with antiepileptics and antidepressants.
S
ince the earliest descriptions of pain related to injury of the nervous system, it has been recognized that the characteristics of this type of pain differ markedly from those of pain due to nonneural tissue damage. Later as new analgesics were developed, it became clear that neurogenic pain was very often refractory to these drugs. Recently neuropathic pain is defined as "pain initiated or caused by a primary lesion or dysfunction in the nervous system." Inflammatory reaction and neuropathic pain are often considered to be distinct entities. The development of neuropathic pain involves not only neuron but also inflammatory cells, chemokines, and glial cells. Treatment of neuropathic pain is difficult and frequently unrewarding. The basic principles are the identification and elimination of the underlying pathologic mechanism that maintains central sensitization; the use of nonsteroidal anti-inflammatory drugs to reduce peripheral sensitization and modulate the activity of nociceptors; the use of tricyclic antidepressants to induce sleep and decrease lancinating and burning neuropathic pain; a trial of gabapentin, pregabalin, lamotrigine and topamax; the use of lidocaine patch for intractable trigeminal neuralgia; sympathetic blockade for complex regional pain syndrome while patients are stick sympathetically maintained; dorsal column stimulation; intrathecal therapies including morphine, clonidine, and GABA B agonists when other less invasive therapies have failed. In this article we reviewed the role of peripheral inflammation for development of neuropathic pain, diagnosis, and new opportunities for treatment of neuropathic pain, especially focused on medical treatments with antiepileptics and antidepressants. Step 1 Assess pain and establish the diagnosis of NP; if uncertain about the diagnosis, refer to a pain specialist or neurologist Establish and treat the cause of NP; if uncertain about availability of treatments addressing NP etiology, refer to appropriate specialist Identify relevant comorbidities (e.g., cardiac, renal, or hepatic disease, depression, gait instability) that might be relieved or exacerbated by NP treatment, or that might require dosage adjustment or additional monitoring of therapy Explain the diagnosis and treatment plan to the patient, and establish realistic expectations
Step 2 Initiate therapy of the disease causing NP, if applicable Initiate symptom treatment with one or more of the following:
• A secondary amine TCA (nortriptyline, desipramine) or an SSNRI (duloxetine, venlafaxine)
• A calcium channel a2-d ligand, either gabapentin or pregabalin • For patients with localized peripheral NP: topical lidocaine used alone or in combination with one of the other first-line therapies • For patients with acute neuropathic pain, neuropathic cancer pain, or episodic exacerbations of severe pain, and when prompt pain relief during titration of a first-line medication to an efficacious dosage is required, opioid analgesics or tramadol may be used alone or in combination with one of the first-line therapies Evaluate patient for non-pharmacologic treatments, and initiate if appropriate
Step 3 Reassess pain and health-related quality of life frequently If substantial pain relief (e.g., average pain reduced to 63/10) and tolerable side effects, continue treatment If partial pain relief (e.g., average pain remains P4/10) after an adequate trial (see Table 3 ), add one of the other first-line medications If no or inadequate pain relief (e.g., < 30% reduction) at target dosage after an adequate trial (see Table 3 ), switch to an alternative first-line medication
Step 4 If trials of first-line medications alone and in combination fail, consider second-and third-line medications or referral to a pain specialist or multidisciplinary pain center TCA: tricyclic antidepressant, SSNRI: selective serotonin and norepinephrine reuptake inhibitor 
